Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,092 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,092 Papers indexed
371 Papers AI scored
37,092 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37092 results
B
AI -
Base 77.24
Rank 77.24
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 26.2; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 46.2; sample size: 20.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 77.23
Rank 77.23
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 61.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era.
PMID 41347988 Published: 2025-12-05 Ingested: 2026-08-02 12:05 AM Hematology. American Society of Hematology. Education Program
AI -
Base 77.22
Rank 77.22
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 58.6; sample size: 20.0; recency: 100.0; abstract quality: 65.0.

B
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.
PMID 40313040 Published: 2025-05-01 Ingested: 2026-08-02 12:04 AM Pediatric blood & cancer
AI -
Base 77.22
Rank 77.22
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 36.1; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Base 77.22
Rank 77.22
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 66.1; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
Psychometric evaluation of the 28-item coping orientation to problems experienced inventory (Brief COPE) amongst parents of preschool children from low-income backgrounds.
PMID 42494941 Published: 2026-07-10 Ingested: 2026-08-02 12:07 AM International journal of nursing studies advances
AI -
Base 77.2
Rank 77.2
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 16.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Base 77.2
Rank 77.2
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 26.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 56.0; sample size: 60.0; recency: 100.0; abstract quality: 65.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 77.2/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 16.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 214 of 3091
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic